Compositions and methods for modulating EMT and uses thereof
View Patent ↗The invention provides compositions and methods useful for modulating epithelial-mesenchymal transition (EMT). Certain of the compositions and methods are useful for inducing epithelial cells to undergo an EMT. The invention further provides cells generated using the inventive methods and methods of use thereof. Certain of the compositions and methods are useful for inhibiting epithelial cells from undergoing an EMT. Certain of the compositions and methods are useful for inhibiting EMT in a subject in need thereof.
1. A composition comprising one or more compounds selected from each of at least three of the following groups: (a) compounds that stimulate transforming growth factor (TGF)-beta pathway signaling; (b) compounds that stimulate canonical Wnt pathway signaling; (c) compounds that stimulate non-canonical Wnt pathway signaling; and (d) compounds that perturb cell adhesion, wherein the composition comprises at least one compound from group (b), and wherein the at least one compound of (b) disinhibits canonical Wnt pathway signaling by inhibiting a Dikkopf (DKK) or soluble Frizzled-related proteins (SFRP) family member.
2. The composition of claim 1 , wherein the composition comprises one or more compounds selected from each of the following groups: (a) compounds that stimulate TGF-beta pathway signaling; and (c) compounds that stimulate non-canonical Wnt pathway signaling.
3. The composition of claim 1 , comprising at least one compound from group (a), wherein the at least one compound of (a) comprises a TGF beta protein.
4. The composition of claim 1 , comprising at least one compound from group (c), wherein the at least one compound of (c) stimulates the Wnt/Ca2+ pathway.
5. The composition of claim 1 , comprising at least one compound from group (c), wherein the at least one compound of (c) comprises a Wnt5a or Wnt 16 protein.
6. The composition of claim 1 , comprising at least one compound from group (d), wherein the at least one compound of (d) perturbs adherens junction or tight junction formation or maintenance.
7. The composition of claim 1 , comprising at least one compound from group (d), wherein the at least one compound of (d) inhibits E-cadherin.
8. The composition of claim 1 , wherein the compounds are present in concentrations effective to induce epithelial cells to undergo an epithelial-mesenchymal transition (EMT).
9. The composition of claim 1 , further comprising epithelial cells.
10. The composition of claim 1 , comprising TGF-beta 1, Wnt5a, a DKK1 inhibitor, an SFRP1 inhibitor, and an E-cadherin inhibitor.
11. The composition of claim 10 , wherein the DKK1 inhibitor is an anti-DKK1 antibody.
12. The composition of claim 10 , wherein the SFRP1 inhibitor is an anti-SFRP1 antibody.
13. The composition of claim 10 , wherein the E-cadherin inhibitor is an anti-E-cadherin antibody.
14. The composition of claim 1 , further comprising cell culture medium.
15. A composition comprising one or more compounds selected from each of at least three of the following groups: (a) compounds that stimulate TGF-beta pathway signaling; (b) compounds that stimulate canonical Wnt pathway signaling; (c) compounds that stimulate non-canonical Wnt pathway signaling; and (d) compounds that perturb cell adhesion, wherein the composition comprises at least one compound from group (d), wherein the at least one compound of (d) perturbs adherens junction or tight junction formation or maintenance.
16. A composition comprising one or more compounds selected from each of at least three of the following groups: (a) compounds that stimulate TGF-beta pathway signaling; (b) compounds that stimulate canonical Wnt pathway signaling; (c) compounds that stimulate non-canonical Wnt pathway signaling; and (d) compounds that perturb cell adhesion, wherein the compounds are present in concentrations effective to induce epithelial cells to undergo an EMT.